Resources:
Join us on 18 April for the first webinar on using RWE to demonstrate the value of cancer treatments. A keynote address will outline the EU policy context in terms of the Beating Cancer Plan. A panel including policy, clinical, patient, industry and HTA experts will then discuss the opportunities and challenges of RWE generation for cancer treatments in the EU in light of other policy developments such as the European Health Data Space and the HTAR.
European Cancer Organisation Past President & Medical Oncologist
Evidence Based Health Policy Consultant, RWE4Decisions Secretariat
Professor of Cellular Biology at the Université de Paris, Vice-Chair of the EU Cancer Mission
Co-Rapporteur of the European Health Data Space for the Committee on Environment, Public Health and Food Safety (ENVI)
Director, EUCAN Oncology Access and Reimbursement Policy, Takeda
Head, Membership & Alliances, Lymphoma Coalition
Analyst, Swedish Dental and Pharmaceutical Benefits Agency (TLV)
Medical oncologist, Genolier Cancer Center & Immediate Past-President, European Cancer Organisation
Evidence Based Health Policy Consultant, RWE4Decisions Secretariat
Under the EU Health Technology Assessment Regulation (HTAR), oncology products and Advanced Therapeutic Medicinal Products will be the first to undergo Joint Clinical Assessments, starting in January 2025. As there is often a paucity of clinical evidence available for these highly innovative treatments, the 2023 RWE4Decisions webinar series will consider the potential for use of RWD, given there is no EU-wide guidance on RWE generation or use.
Public Webinar: From Policy to Practice: EHDS Implementation to Support Better Real-World Evidence for HTA/Payers
RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA
Public Webinar: HTA/Payer Collaboration in the Nordics: The Role of Real-World Evidence
